A big moment: regulating personal genome services


A big moment: regulating personal genome services

An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions.

The technology of genetic screening has come on leaps and bounds since the Human Genome Project finished sequencing the entire human genome, after 13 years’ work, in 2003.

Now direct-to-consumer genetic testing companies can look at sections of your genome to determine risks of developing certain diseases, and deliver the results in a matter of weeks.

California-based 23andMe offers such a service. Describing itself as the largest DNA ancestry service in the world, 23andMe’s personal genome service (PGS) will analyse the DNA it receives from the saliva kit it sends and provide a detailed report about a person’s risks of developing certain diseases.

direct-to-consumer genetic tests, Personal Genome Service, regulation, 23andMe, FDA